Advanced search
1 file | 869.60 KB

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

(2011) EUROPEAN JOURNAL OF CANCER. 47(15). p.2331-2340
Author
Organization
Keywords
CELL LUNG-CANCER, SUPPORTIVE CARE, TRIAL, CARBOPLATIN, DOCETAXEL, ERLOTINIB, GEMCITABINE, COMBINATION, PACLITAXEL, PLUS, EORTC, EGFR, Gefitinib, Chemotherapy, Non-small cell lung cancer

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 869.60 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Gaafar, Rabab M, Veerle Surmont, Giorgio V Scagliotti, Rob J Van Klaveren, Demetris Papamichael, John J Welch, Baktiar Hasan, Valter Torri, and Jan Van Meerbeeck. 2011. “A Double-blind, Randomised, Placebo-controlled Phase III Intergroup Study of Gefitinib in Patients with Advanced NSCLC, Non-progressing After First Line Platinum-based Chemotherapy (EORTC 08021/ILCP 01/03).” European Journal of Cancer 47 (15): 2331–2340.
APA
Gaafar, R. M., Surmont, V., Scagliotti, G. V., Van Klaveren, R. J., Papamichael, D., Welch, J. J., Hasan, B., et al. (2011). A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). EUROPEAN JOURNAL OF CANCER, 47(15), 2331–2340.
Vancouver
1.
Gaafar RM, Surmont V, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, et al. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). EUROPEAN JOURNAL OF CANCER. 2011;47(15):2331–40.
MLA
Gaafar, Rabab M, Veerle Surmont, Giorgio V Scagliotti, et al. “A Double-blind, Randomised, Placebo-controlled Phase III Intergroup Study of Gefitinib in Patients with Advanced NSCLC, Non-progressing After First Line Platinum-based Chemotherapy (EORTC 08021/ILCP 01/03).” EUROPEAN JOURNAL OF CANCER 47.15 (2011): 2331–2340. Print.
@article{2044481,
  author       = {Gaafar, Rabab M and Surmont, Veerle and Scagliotti, Giorgio V and Van Klaveren, Rob J and Papamichael, Demetris and Welch, John J and Hasan, Baktiar and Torri, Valter and Van Meerbeeck, Jan},
  issn         = {0959-8049},
  journal      = {EUROPEAN JOURNAL OF CANCER},
  keyword      = {CELL LUNG-CANCER,SUPPORTIVE CARE,TRIAL,CARBOPLATIN,DOCETAXEL,ERLOTINIB,GEMCITABINE,COMBINATION,PACLITAXEL,PLUS,EORTC,EGFR,Gefitinib,Chemotherapy,Non-small cell lung cancer},
  language     = {eng},
  number       = {15},
  pages        = {2331--2340},
  title        = {A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)},
  url          = {http://dx.doi.org/10.1016/j.ejca.2011.06.045},
  volume       = {47},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: